ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 153,03
0,96%
Dow Jones
38 884,26
0,08%
DAX
18 509,36
0,38%
Brent Oil
82,125
-0,89%
Bitcoin
62 211,44
-0,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) Actualités

OKYO OKYO Pharma Ltd

1,4242
0,00 (0,00%)
Avant marché
Dernière mise à jour : 13:00:08
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
OKYO Pharma Ltd OKYO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 1,4242 13:00:08
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,4242
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/5/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202413:00GLOBEOKYO Pharma Announces Participation in May 2024 Investor..
30/4/202413:00GLOBEOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
09/4/202401:00GLOBEOKYO Pharma to Reschedule Key Opinion Leader Event in Dry..
02/4/202413:00GLOBEOKYO Pharma Announces Upcoming Presentation of OK-101 Phase..
22/3/202412:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
21/3/202412:00GLOBEOKYO Pharma to Host Key Opinion Leader Event to Discuss New..
20/3/202412:00GLOBEOKYO Pharma to Release New and Comprehensive Data from Phase..
09/2/202413:36IHNWOKYO Pharma Receives FDA Approval of IND for OK-101 in..
09/2/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/2/202413:00GLOBEOKYO Pharma Receives FDA Approval of IND for OK-101 in..
31/1/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202413:00GLOBEOKYO Pharma Announces Distinguished Ophthalmologists with..
08/1/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202413:00GLOBEOKYO Pharma Announces OK-101 Successfully Achieved..
05/1/202415:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202415:30GLOBEOKYO Pharma to Present at the Biotech Showcase Conference in..
21/12/202313:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202323:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/12/202322:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202313:00GLOBEOKYO Pharma Announces Last Patient Enrolled in OK-101 Phase..
29/11/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202321:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202321:59EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/10/202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202312:00GLOBEOKYO Pharma Announces $5.84 Million Cash Raise and Payables..
10/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/10/202317:34IHNWOKYO Pharma Announces Filing of an Investigational New Drug..
09/10/202313:00GLOBEOKYO Pharma Announces Filing of an Investigational New Drug..
05/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202313:00GLOBEOKYO Pharma Announces Positive Safety Data Profile for the..
15/9/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/9/202313:00GLOBEOKYO Pharma Announces Closing of $4.0 Million Registered..
15/9/202312:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/9/202316:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202316:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202315:15GLOBEOKYO Pharma Announces Pricing of $4.0 Million Registered..
14/9/202314:45GLOBEOKYO Pharma Limited Announces Withdrawal of Public Offering
13/9/202322:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/9/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202322:05GLOBEOKYO Pharma Announces Public Offering of Ordinary Shares
08/9/202313:04IHNWOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
08/9/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/9/202313:00GLOBEOKYO Pharma Completes Enrollment in Phase 2 Clinical Trial..
30/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202313:00GLOBEOKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2..
29/8/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202313:00GLOBEOKYO Pharma Limited Regains Compliance with Nasdaq Listing..

Dernières Valeurs Consultées

NASDAQ
OKYO
OKYO Pharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés